798 Impact of third line ZD 1839 therapy on patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme)
Ejc Supplements（2003）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要